JP2017516756A5 - - Google Patents

Download PDF

Info

Publication number
JP2017516756A5
JP2017516756A5 JP2016562005A JP2016562005A JP2017516756A5 JP 2017516756 A5 JP2017516756 A5 JP 2017516756A5 JP 2016562005 A JP2016562005 A JP 2016562005A JP 2016562005 A JP2016562005 A JP 2016562005A JP 2017516756 A5 JP2017516756 A5 JP 2017516756A5
Authority
JP
Japan
Prior art keywords
composition
amino acid
use according
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016562005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516756A (ja
JP6649895B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/026415 external-priority patent/WO2015161220A1/en
Publication of JP2017516756A publication Critical patent/JP2017516756A/ja
Publication of JP2017516756A5 publication Critical patent/JP2017516756A5/ja
Priority to JP2020005711A priority Critical patent/JP7315487B2/ja
Application granted granted Critical
Publication of JP6649895B2 publication Critical patent/JP6649895B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016562005A 2014-04-18 2015-04-17 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法 Active JP6649895B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020005711A JP7315487B2 (ja) 2014-04-18 2020-01-17 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201461981519P 2014-04-18 2014-04-18
US61/981,519 2014-04-18
US201461984393P 2014-04-25 2014-04-25
US61/984,393 2014-04-25
US201462011482P 2014-06-12 2014-06-12
US62/011,482 2014-06-12
US201462036066P 2014-08-11 2014-08-11
US62/036,066 2014-08-11
US201462088374P 2014-12-05 2014-12-05
US62/088,374 2014-12-05
PCT/US2015/026415 WO2015161220A1 (en) 2014-04-18 2015-04-17 Methods for increasing red blood cell levels and treating sickle-cell disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020005711A Division JP7315487B2 (ja) 2014-04-18 2020-01-17 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法

Publications (3)

Publication Number Publication Date
JP2017516756A JP2017516756A (ja) 2017-06-22
JP2017516756A5 true JP2017516756A5 (enExample) 2018-05-31
JP6649895B2 JP6649895B2 (ja) 2020-02-19

Family

ID=54324622

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016562005A Active JP6649895B2 (ja) 2014-04-18 2015-04-17 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
JP2020005711A Active JP7315487B2 (ja) 2014-04-18 2020-01-17 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
JP2021130588A Pending JP2021175755A (ja) 2014-04-18 2021-08-10 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020005711A Active JP7315487B2 (ja) 2014-04-18 2020-01-17 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
JP2021130588A Pending JP2021175755A (ja) 2014-04-18 2021-08-10 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法

Country Status (11)

Country Link
US (2) US20150361163A1 (enExample)
EP (2) EP3131931B1 (enExample)
JP (3) JP6649895B2 (enExample)
AP (1) AP2016009549A0 (enExample)
AU (2) AU2015247459A1 (enExample)
BR (1) BR112016024319B1 (enExample)
CA (1) CA2962197C (enExample)
ES (1) ES2845650T3 (enExample)
MA (1) MA52909A (enExample)
MX (2) MX388380B (enExample)
WO (1) WO2015161220A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2781222B1 (en) 2005-11-23 2017-08-02 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2481415B1 (en) 2007-02-09 2019-09-11 Acceleron Pharma Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP5912078B2 (ja) 2009-06-08 2016-04-27 アクセルロン ファーマ， インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
EP3290439B1 (en) 2009-06-12 2020-09-02 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
TWI730949B (zh) 2014-12-03 2021-06-21 美商西建公司 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途
SI3286206T1 (sl) 2015-04-22 2021-07-30 Biogen Ma Inc. Novi hibridni proteini ligandske pasti actriib za zdravljenje bolezni zaradi izgube mišične mase
EP3298034A4 (en) 2015-05-20 2019-02-13 Celgene Corporation IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS
EP3370754B1 (en) * 2015-11-04 2026-04-29 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
WO2017083281A1 (en) * 2015-11-09 2017-05-18 Albert Einstein College Of Medicine, Inc. Method of ameliorating side effects of sickle cell disease treatments
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
GB2550114A (en) * 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists
CN116531490A (zh) 2016-07-15 2023-08-04 阿塞勒隆制药公司 用于治疗肺高血压的组合物和方法
HUE067225T2 (hu) 2016-07-27 2024-10-28 Acceleron Pharma Inc Mielofibrózis kezelésére szolgáló készítmények
CA3039074A1 (en) * 2016-10-05 2018-04-12 Acceleron Pharma Inc. Compositions and method for treating kidney disease
KR102761094B1 (ko) 2016-10-05 2025-02-03 악셀레론 파마 인코포레이티드 변이체 actriib 단백질 및 이의 용도
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
CN119241685A (zh) 2016-11-10 2025-01-03 科乐斯疗法公司 激活素受体iia型变体及其使用方法
US20200087367A1 (en) * 2017-02-06 2020-03-19 Acceleron Pharma Inc. Compositions and methods for treating heart failure
CN111801112A (zh) 2017-11-09 2020-10-20 科乐斯疗法公司 激活素受体iia型变体及其使用方法
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
WO2019217715A1 (en) 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
CA3176735A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4142769A4 (en) 2020-04-28 2024-05-15 Acceleron Pharma Inc. ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
TW202400625A (zh) * 2022-06-15 2024-01-01 日商肽夢想股份有限公司 肽以及包含肽之劑

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
NZ502795A (en) 1995-04-11 2001-09-28 Gen Hospital Corp Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6011577A (en) 1997-06-30 2000-01-04 Polaroid Corporation Modular optical print head assembly
JP2001513982A (ja) 1997-08-29 2001-09-11 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド フォリスタチン−３
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
JP2002533726A (ja) 1998-12-28 2002-10-08 サネシス ファーマシューティカルス インコーポレイテッド 結合のための小有機分子リガンドの同定
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
NZ513642A (en) 1999-01-21 2004-02-27 Metamorphix Inc Growth differentiation factor inhibitors and uses therefor
DE60042021D1 (de) 1999-07-29 2009-05-28 Gilead Sciences Inc Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US20070135336A1 (en) 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
EP3489257A1 (en) 2004-07-23 2019-05-29 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP2781222B1 (en) 2005-11-23 2017-08-02 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2481415B1 (en) 2007-02-09 2019-09-11 Acceleron Pharma Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
KR20110031951A (ko) * 2008-06-26 2011-03-29 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
TWI626945B (zh) * 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
KR20140084211A (ko) * 2011-10-17 2014-07-04 악셀레론 파마 인코포레이티드 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물
BR112014015003A2 (pt) * 2011-12-19 2019-09-24 Amgen Inc composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral
EP2912462B1 (en) * 2012-10-24 2019-08-07 Celgene Corporation Biomarker for use in treating anemia

Similar Documents

Publication Publication Date Title
JP2017523140A5 (enExample)
Kandasamy et al. TGF-β signaling: a therapeutic target to reinstate regenerative plasticity in vascular dementia?
JP2021050201A (ja) 成長因子モジュレーションのための組成物および方法
JP6865585B2 (ja) 成長分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP4947717B2 (ja) アンジオポエチン様４タンパク質のインヒビター、組み合わせ、およびそれらの使用
Paleolog The vasculature in rheumatoid arthritis: cause or consequence?
CN110582511B (zh) 抗N3pGlu淀粉状蛋白β肽抗体及其用途
JP2021176873A (ja) 高親和性ｓｉｒｐ−アルファ試薬
KR102366682B1 (ko) 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도
JP2017101068A5 (enExample)
JP2019522022A5 (enExample)
JP2017537921A5 (enExample)
US20210340238A1 (en) TGFß1 INHIBITORS AND USE THEREOF
US9333257B2 (en) FGFR1 antibodies and treatment of cancer
JP2017509647A5 (enExample)
US9920105B2 (en) Human ferritin-derived fusion polypeptide
JP2010522208A (ja) 安定な抗体処方物
US20150352186A1 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
US20070265203A1 (en) Methods and compositions for modulation of blood-neural barrier
JP2003534384A (ja) 神経保護性ペプチド
US20160215045A1 (en) VEGFA/Ang2 Compounds
CA2890166C (en) Formulation for bispecific t-cell engagers (bites)
KR20180134876A (ko) 인간화 항 clever-1 항체 및 이의 용도
JP2008501701A (ja) 新形成または新生脈管構造の検出、画像化および処置のための血管標的
CN110997718A (zh) 血管内皮生长因子/抗纤连蛋白抗体融合蛋白